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Petabolic Syndrome and Risk of
ardiovascular Events After Myocardial Infarction
iacomo Levantesi, MD,* Alejandro Macchia, MD,* RosaMaria Marfisi, MS,* Maria G. Franzosi, MSC,†
ldo P. Maggioni, MD,‡ Gian L. Nicolosi, MD,§ Carlo Schweiger, MD, Luigi Tavazzi, MD,¶
ianni Tognoni, MD,* Franco Valagussa, MD,# Roberto Marchioli, MD,*
n behalf of the GISSI-Prevenzione Investigators
anta Maria Imbaro, Firenze, Milano, Pavia, Monza, and Pordenone, Italy
OBJECTIVES We aimed to assess the prevalence and prognostic role of metabolic syndrome (METS) and
diabetes in post-myocardial infarction (MI) patients.
BACKGROUND Diabetes is a well known risk factor for patients with previous MI, but glycemic dysmetabo-
lism develops over a protracted period of time. Scanty data are available on the role of METS
in patients with previous MI.
METHODS Adjusted Cox’s regression models, having diabetes, death, major cardiovascular events
(CVE), and hospitalization for congestive heart failure (CHF) during follow-up as outcome
events, were fitted on 11,323 patients with prior MI enrolled in the GISSI-Prevenzione Trial.
RESULTS At baseline, 21% and 29% of patients had diabetes mellitus and METS, respectively. The
METS patients had a significant (93%) increased risk of diabetes during follow-up. As
compared with control subjects, the probability of death and CVE were higher in both
METS (29%, p  0.002; 23%, p  0.005) and diabetic patients (68%, p 0.0001;
47%, p 0.0001), although diabetic but not METS patients were more likely to be
hospitalized for CHF (89%, p0.0003 and24%, p 0.241). Moderate (6% to10%)
and substantial (10%) weight reduction were associated with a significant (18% and 41%,
respectively) decreased risk of diabetes. Weight gain was significantly associated with
increased risk of diabetes. The risk conferred by METS and diabetes tended to be higher
among women.
CONCLUSIONS In patients with MI, METS and diabetes were highly prevalent and are associated with
increased risk of death and CVE. Diabetes is also associated with increased risk of
hospitalization for CHF. Weight reduction significantly decreased the risk of becoming
diabetic in patients with METS. (J Am Coll Cardiol 2005;46:277–83) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.03.062American College of Cardiology Foundation
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aype 2 diabetes mellitus is a well recognized risk factor for
ardiovascular morbidity and mortality (1–5). Glucose me-
abolism abnormalities, however, develop over a prolonged
eriod of time during which individuals are at high risk of
ardiovascular events despite glucose levels that could be
onsidered as normal (6–10). This period is characterized
y a progressive resistance to the action of insulin, a process
alled insulin resistance (IR) that usually clusters with
everal cardiovascular risk factors (11–15). The diagnosis of
R is complex and cannot be easily performed in clinical
ractice (16 –19); however, the metabolic syndrome
METS) is characterized by the clustering of risk factors
elated to IR and is considered to be an early indicator of
mpaired glucose metabolism (20–24). The diagnosis of
ETS proposed by the National Cholesterol Education
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GISSI); Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO); Istituto
i Ricerche Farmacologiche Mario Negri – Consorzio Mario Negri Sud, Santa Maria
mbaro, Italy. The names of the GISSI-Prevenzione Investigators are listed in
eference 26.d
Manuscript received November 9, 2004; revised manuscript received March 16,
005, accepted March 29, 2005.rogram Adult Treatment Panel III (NCEP-ATP III) is
ased on simple clinical criteria (20) and is considered a
rognostic indicator of vascular risk in patients with no
vert coronary artery disease (20–24).
Because scanty data are available on the prognostic role of
ETS in patients with previous myocardial infarction (MI)
25), we analyzed the GISSI-Prevenzione Trial database
26) to assess the prevalence of METS and diabetes as well
s their association with cardiovascular events in post-MI
atients.
ETHODS
atients. A detailed description of the study has been
eported previously (26). Briefly, 11,323 patients with recent
3 months, median 16 days) MI were enrolled in the
ISSI-Prevenzione Trial, a multicenter open-label clinical
tudy, with blinded validation of events and follow-up
uration of 3.5 years, on the efficacy of polyunsaturated fatty
cids (PUFA) (1 g daily) and vitamin E (300 mg daily).
linical, laboratory, and instrumental evaluation of the
atients recruited in the study were carried out at baseline
nd follow-up visits that were scheduled at 6, 12, 18, 30,
nd 42 months.
The outcomes measures for this analysis were: diabetes
evelopment during follow-up (defined as fasting glucose
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The Role of Metabolic Syndrome in Post-MI Patients July 19, 2005:277–83126 mg/dl or antidiabetic treatment) in non-diabetic
atients at baseline, all-cause mortality, cumulative rate of
ardiovascular events (CVE) (cardiovascular death, nonfatal
I, nonfatal stroke), and development of congestive heart
ailure (CHF) that was assessed according to hospitalization
or CHF during follow-up in patients with no heart failure
t baseline.
The analysis on overall mortality and CVE was carried
ut in 10,384 patients (i.e., after excluding 939 patients who
ad missing data for METS components at baseline). For
he analysis of diabetes development during follow-up, we
xcluded 2,139 patients with diabetes at baseline and 777
ases with no measurement of glucose levels during follow-
p. The analysis on CHF hospitalizations was carried out
n 8,417 patients who were free from CHF (New York
eart Association [NYHA] functional class II or physician-
eported CHF) at baseline and had complete information
or CHF assessment (NYHA functional class, medication
eport) at least at one scheduled follow-up visit.
To assess the effect of weight change on the risk of CVE
nd diabetes development during follow-up, 7,027 patients
ho had body weight measurements both at baseline and at
he first follow-up visit and who were free of cardiovascular
vents and diabetes until the first follow-up visit were
ncluded in the analysis. We also evaluated the effect of
eight change in 4,422 patients with body mass index
BMI) 25 kg/m2. We considered patients who had no or
light decrement of body weight (5%) as the reference
lass. Body weight changes between the baseline and the
rst follow-up visit were defined as moderate (6% to
10%) and substantial (10%) weight reductions,
hereas weight increments were defined as light (0% to
5%), moderate (6% to 10%), and substantial
10%).
For the diagnosis of METS at baseline, we modified the
CEP-ATP III criteria for abdominal obesity by using the
edian value of BMI 26 kg/m2 instead of the waist
ircumference, which was not available. The cutoff for BMI
t the median value was indicative of overweight, and being
ver the upper limit of normality, it could be considered a
roxy of visceral adiposity. Accordingly, diagnosis of METS
as established when non-diabetic subjects had at least
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
BMI  body mass index
CHF  congestive heart failure
CVE  cardiovascular events
IR  insulin resistance
METS  metabolic syndrome
MI  myocardial infarction
NCEP-ATP III  National Cholesterol Education
Program Adult Treatment Panel III
NYHA  New York Heart Association
PUFA  polyunsaturated fatty acidshree of the following five criteria: visceral adiposity (BMI p26 kg/m2), high triglycerides (150 mg/dl), low high-
ensity lipoprotein cholesterol (40 mg/dl in men and50
g/dl in women), hypertension (systolic blood pressure 
30 mm Hg or diastolic blood pressure 85 mm Hg or
ntihypertensive treatment or history of hypertension), and
mpaired fasting glucose (110 mg/dl and 126mg/dl).
or diagnosis of METS, we did a sensitivity analysis by
sing a BMI value of 28 and 29 kg/m2 (corresponding to the
pper quartile and upper quintile) with no substantial
ifference in terms of prognostic capacity of METS (data
ot shown). Diabetes at baseline was diagnosed if either
lucose 126 mg/dl, patients were on anti-diabetic treat-
ent, or physician-reported diabetes.
tatistical methods. One-way analysis of variance and
hi-square test were used to test continuous and categorical
ariables at baseline, respectively.
Cox proportional models were fitted with all-cause mor-
ality, CVE, late onset CHF, and new diagnosis of diabetes
uring follow-up as outcome measures. The following
otential confounders were included in the multivariable
odels: 1) age and gender; 2) electrical instability (defined
s10 premature ventricular beats/h, sustained or repetitive
rrhythmias during 24-h Holter monitoring), residual isch-
mia (angina pectoris, positive exercise testing), ejection
raction; 3) smoking, total cholesterol, peripheral vascular
isease; and 4) n-3 PUFA, vitamin E, antiplatelet agents,
ngiotensin-converting enzyme (ACE) inhibitors, statins,
nd beta-blockers. The multivariate model that was aimed
t assessing the effect of weight reduction on risk of late
nset diabetes also included BMI levels measured at base-
ine. Cox proportional hazards event-free survival curves,
djusted for covariates means, were plotted. All probability
alues are two-sided. All computations used the SAS
tatistical package (SAS Institute Inc., Cary, North Caro-
ina).
ESULTS
aseline descriptive statistics. Out of a total of 10,384
atients, 2,139 (20.6%) had diabetes mellitus and 3,047
29.3%) had METS (Table 1). As compared with METS
nd control subjects, diabetic patients were more likely to be
emale, older, and with higher prevalence of peripheral
rtery disease and MI before the index event leading to
ecruitment into the study. Diabetic patients were also more
ikely to have an impaired left ventricular function with
ower levels of ejection fraction and higher prevalence of
YHA functional class II. As to medication use, diabetic
atients were more likely to receive ACE inhibitors and less
ikely to be given aspirin and beta-blockers (Table 1).
Normal and METS patients were much more similar, the
atter group having a higher prevalence of women (12.3% vs.
5.4%, p  0.0001) and of use of beta-blockers, ACE
nhibitors, and aspirin (Table 1).
There were some minor differences at baseline between
atients who were included in the analysis and those who
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July 19, 2005:277–83 The Role of Metabolic Syndrome in Post-MI Patientsere not because of missing data. As compared with
atients who were included in the analysis, those excluded
ere younger (58 vs. 60 years), less likely to be in NYHA
unctional class II (8% vs. 10%), and less often treated with
ntiplatelet drugs (85% vs. 92%) and beta blockers (36% vs.
5%).
utcome events. As compared with control subjects (Figs.
and 2, Table 2), the probability of death and CVE were
igher in both METS (29%, p  0.002; 23%, p 
.005) and diabetic patients (68%, p 0.0001; 47%, p
0.0001). Diabetic but not METS patients (Fig. 3, Table
) were more likely to be hospitalized for CHF (89%, p
.0003) and METS (24%, p  0.241), as compared with
ontrol subjects. In addition to a near two-fold increased
isk of developing diabetes (93%, p  0.0001; Fig. 4),
able 1. Baseline Characteristics of 10,384 Patients of the GISSI
Normal Patients
n  5,198
ean age (SD) 59.0  10.8
omen (%) 638 (12.3)
revious MI (%) 586 (11.3)
ean total cholesterol (SD) 209  42
eripheral artery disease (%) 195 (3.8)
YHA functional class II (%) 471 (9.1)
ean LVEF (SD) 53  10
ntiplatelet drugs (%) 4,769 (91.7)
eta-blockers (%) 2,350 (45.2)
tatins (%) 1,116 (22.1)
CE inhibitors (%) 2,150 (41.4)
or statistical inference: the one-way analysis of variance for continuous variables an
ACE  angiotensin-converting enzyme; LVEF  left ventricular ejection fraction
ssociation.
igure 1. Survival curves of control subjects (bottom black line), patients
ith metabolic syndrome (middle black line), and diabetic patients (top
lack line). Normal patients: relative risk 1.00 (reference category);
etabolic syndrome patients: relative risk 1.29, 95% confidence interval
CI) 1.10 to 1.51, p  0.002; diabetic patients: relative risk 1.68, 95% CI
.44 to 1.95, p  0.0001. Cox proportional hazard model adjusted for age,
ender, smoking habits, total cholesterol, presence of peripheral vascular
isease, electrical instability, residual ischemia, left ventricular ejection
raction, n-3 polyunsaturated fatty acids, vitamin E, antiplatelet agents,
ngiotensin-converting enzyme inhibitors, statins at six months, and
eta-blockers.
r
METS patients had a risk of diabetes steeply increasing
ith the number of diagnostic components for METS. Of
he METS patients, 2,120 (70%), 841 (28%), and 86 (3%)
ad three, four, and five diagnostic components for METS,
espectively. As compared with patients with three compo-
ents for METS, the risk of developing diabetes was 60% (p
0.0001) and 273% (p  0.0001) higher in patients with
our and five components for METS diagnosis, respectively
Fig. 5).
Diabetic patients with fewer than three components of
ETS had a near significant 40% (p  0.067) increased
isk of death compared with METS with four or five
omponents, and no difference was apparent as to the risk of
VE between these two groups of patients (p  0.708).
In a subgroup analysis, in patients with METS, women,
s compared with men, had higher risk of developing
iabetes (169% vs. 86% [p  0.092]), mortality (40% vs.
9% [p  0.679]), and CVE (51% vs. 20% [p  0.298]),
lthough these differences were not statistically significant.
ompared with diabetic men, diabetic women had signifi-
ant higher risks of death (193% vs. 54% [p  0.006]) and
f CVE (146% vs. 32% [p  0.004]).
venzione Database
ETS Patients
n  3,047
Diabetic Patients
n  2,139 p Value
58.6  10.3 61.9  9.6 0.0001
468 (15.4) 441 (20.6) 0.0001
358 (11.8) 315 (14.8) 0.0001
216  41 207  44 0.0001
102 (3.4) 174 (8.1) 0.0001
271 (8.9) 320 (15.0) 0.0001
53  10 51  11 0.0001
2,819 (92.5) 1,928 (90.1) 0.009
1,523 (50.0) 776 (36.3) 0.0001
628 (21.4) 390 (19.2) 0.0258
1,500 (49.2) 1,211 (56.6) 0.0001
chi-square test for categorical ones.
S  metabolic syndrome; MI  myocardial infarction; NYHA  New York Heart
igure 2. Cardiovascular event-free survival curves of control subjects
bottom black line), patients with metabolic syndrome (middle black
ine), and diabetic patients (top black line). Normal patients: relative risk
.00 (reference category); metabolic syndrome patients: relative risk 1.23,
5% confidence interval (CI) 1.06 to 1.42, p  0.005; diabetic patients:-Pre
M
d theelative risk 1.47, 95% CI 1.27 to 1.70, p  0.0001. CV  cardiovascular.
ethods as in Figure 1.
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The Role of Metabolic Syndrome in Post-MI Patients July 19, 2005:277–83In 7,027 patients, weight changes during the first six
onths of follow-up had a significant impact on the
robability of developing diabetes (Fig. 6). As compared
ith patients who had a body weight decrement 5% (n 
,066; 29.4%), the risk of developing diabetes was 48%,
7%, and 113% higher in those with a light (n  2,749;
9.1%, p  0.0001), moderate (n  889, 12.6%; p 
.0001), and substantial (n  396; 5.6%, p  0.0001)
eight gain, respectively. But patients who achieved a
oderate (n  678; 9.6%) or substantial (n  249; 3.5%)
eduction of weight had an 18% (p  0.1664) and 41% (p
0.0275) decreased risk of diabetes development during
ollow-up, respectively. A subgroup analysis in 4,422 pa-
ients with BMI25 kg/m2 showed that all levels of weight
hange had slightly, though significantly, increased the risk
f developing diabetes; as compared with patients who had
one to light decrement of body weight (n 1,470; 33.2%),
he risk was 50%, 63%, and 121% higher in those with light
n  1,581; 35.8%, p  0.0001), moderate (n  454;
0.2%, p  0.0001), and substantial weight gain (n  141;
.2%, p  0.0001), respectively. Patients who achieved
Table 2. Final Predictive Models of Overall M
Late-Onset Diabetes for Control Subjects, Pat
Adjusted for Potential Confounders (see Meth
Total Mortality
Normal patients 5,198
n events (%) 384 (7.4) 45
RR (95%CI) 1.00
p value —
METS patients 3,047
n events (%) 258 (8.5) 31
RR (95% CI) 1.29 (1.10–1.51) 1.23 (
p value 0.002
Diabetic patients 2,139
n events (%) 310 (14.5) 41
RR (95%CI) 1.68 (1.44–1.95) 1.47 (
p value 0.0001 
CHF  congestive heart failure; CI  confidence interval; C
 relative risk.
igure 3. Hospitalization for heart failure-free survival curves of control
ubjects (bottom black line), patients with metabolic syndrome (middle
lack line), and diabetic patients (top black line). Normal patients: relative
isk 1.00 (reference category); metabolic syndrome patients: relative risk
.24, 95% confidence interval (CI) 0.86 to 1.79, p  0.241; diabetict
M
atients: relative risk 1.89, 95% CI 1.34 to 2.67, p  0.0003. CHF 
ongestive heart failure. Methods as in Figure 1.oderate (n 550; 12.4%) and substantial (n 226; 5.1%)
eduction of weight, however, had a 15% (p  0.278) and
5% (p  0.02) decreased risk of diabetes development
uring follow-up, respectively.
Weight change during the first six months of follow-up
id not show any significant effect on the risk of CVE in all
,027 patients or in 4,422 overweight patients (data not
hown).
The effects of n-3 PUFA and vitamin E treatments on
utcome measures were consistent with the main results of
he trial and did not differ significantly in the various
ubgroups of patients considered in this analysis (p for
eterogeneity  NS).
ISCUSSION
he main results of this analysis are: 1) in patients who have
ad an MI within the previous three months, IR is a
ommon finding, because 50% of patients had either type 2
iabetes mellitus (20.6%) or METS (29.3%); 2) both
onditions were associated with unfavorable prognosis in
erms of all-cause mortality and CVE; 3) diabetic but not
ETS patients had an increased risk of hospitalization for
igure 4. Diabetes-free survival curves for control subjects (thin black
ine) and patients with metabolic syndrome (thick black line). Normal
atients: relative risk 1.00 (reference category); metabolic syndrome pa-
ity, CVE, Hospitalization for CHF, and
With METS, and Diabetic Patients
Distribution, RR, 95% CI, p Value
Hospitalization
for CHF
Late-Onset
Diabetes
4,306 4,737
) 71 (1.6) 454 (9.6)
1.00 1.00
— —
2,522 2,731
4) 50 (2.0) 486 (17.8)
1.42) 1.24 (0.86–1.79) 1.93 (1.69–2.19)
0.241 0.0001
1,589 —
2) 62 (3.9) —
1.70) 1.89 (1.34–2.67) —
1 0.0003 —
cardiovascular events; METS  metabolic syndrome; RRortal
ients
ods):
CVE
5,198
6 (8.8
1.00
—
3,047
6 (10.
1.06–
0.005
2,139
1 (19.
1.27–
0.000ients: relative risk 1.93, 95% confidence interval 1.69 to 2.19, p  0.0001.
ethods as in Figure 1.
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July 19, 2005:277–83 The Role of Metabolic Syndrome in Post-MI PatientsHF; 4) METS was a strong predictor of diabetes devel-
pment, and this association was related to the number of
omponents of the syndrome; and 5) the risk of developing
iabetes decreased and increased proportionally according
o the magnitude of weight change.
According to our findings, glucose dysmetabolism affects
0% of patients who survive MI. Although results about
iabetes are in line with other reports (2–5), the high
revalence of patients with METS as well as their poor
rognosis underline the need not to overlook this syndrome
n post-MI patients. As in primary prevention (21), meta-
olic syndrome was a strong predictor of late-onset diabetes
n post-MI. We found a strong association between the
umber of factors constituting METS and subsequent risk
f diabetes, which possibly indicates increasing levels of
yperinsulinemia and IR to be associated with a progressive
ncrement of risk. In the Bruneck Study (27), IR correlated
ith the number of METS abnormalities, and IR was
lmost always present when several abnormalities clustered
ogether. This fact underlines the necessity to treat these
atients in order to avoid late-onset diabetes. Lifestyle
abits are paramount in this regard, and we found that
nfavorable weight changes during the first six months after
he index MI were associated with an increased risk of
iabetes mellitus. This finding confirms previous evidence
uggesting that diet, increased physical exercise, and weight
oss (with or without pharmacologic treatment) are able to
educe the risk of diabetes by more than 50% (28–30).
Diagnosis of METS was associated with a risk of CVE
igher than the one of control subjects and lower of that of
iabetic patients. The risk of death among METS patients
as mainly associated with the transformation in diabetes.
n fact, the proportion of deaths in the last 2.5 years of
ollow-up among subjects who were diabetic at baseline or
ETS patients who became diabetic during the first year of
ollow-up was 9.2% and 6.5%, respectively. Conversely,
ontrol subjects and METS patients who did not become
igure 5. Diabetes-free survival curves according to the number of diagnostic
omponents of the metabolic syndrome (METS): three components (bottom
lack line), four components (middle black line), and five components (top
lack line). Three METS components: relative risk 1.00 (reference category);
our METS components: relative risk 1.60, 95% confidence interval (CI) 1.32
o 1.93, p  0.0001; five METS components: relative risk 3.73, 95% CI 2.58
o 5.39, p  0.0001. Methods as in Figure 1.iabetic during the first year follow-up had similar risks of
a
meath in the last 2.5 years of follow-up (4.7% and 5.0%,
espectively). These findings suggest that METS is a syn-
rome somewhere in the middle between normal patients
nd those with diabetes: about 10% of patients with METS
ecame diabetic after one year of follow-up, and their risk of
eath increased and became intermediate between that of
ubjects who were normal or diabetic at baseline.
Insulin resistance is often present several years before the
nset of manifest hyperglycemia (6–10), and METS can
ndicate a state of IR and hyperinsulinemia (20,31–33), but
ithout abnormal glucose levels. Because of the stricter
elationship of macrovascular complications with hyperin-
ulinemia than with hyperglycemia (11,34–36), METS
ould represent an early indicator of increased vascular risk,
hereas diabetes could be considered the last step of a
rogressive and long-term phenomenon involving increased
R (6–10).
Our findings underline the need to identify precociously
nd treat more aggressively patients with METS with
oronary heart disease who have an absolute cardiovascular
isk that is definitely higher than that of primary prevention.
hese findings confirm the clinical utility of METS and
iabetes diagnoses to identify patients at high risk of hard
vents who may benefit from specific preventive pharmaco-
ogic treatments such as targeting lower levels of low-
ensity lipoprotein (LDL) cholesterol (37); these findings
lso extend previous evidence of the prognostic role of
ETS in patients without coronary heart disease to those
ith previous MI (21–24).
We noted that the risk conferred by METS and diabetes
iagnosis tended to be higher among female patients than
ale subjects, despite correction by major confounding. The
igure 6. Relative risk (RR) of diabetes according to body weight variation
t six months after recruitment. Reference category: weight change 5%
RR 1.00); weight change from 0% to 5% (RR 1.48, 95% confidence
nterval (CI) 1.25 to 1.75, p 0.0001); weight change from6% to10%
RR 1.57, 95% CI 1.26 to 1.96, p 0.0001); weight change from10%
RR 2.13, 95% CI 1.60 to 2.83, p  0.0001); weight change from 6% to
10% (RR 0.82, 95% CI 0.63 to 1.08, p  0.1664); weight change
10% (RR 0.59, 95% CI 0.37 to 0.94, p  0.0275). Cox proportional
azard model adjusted for age, gender, body mass index, smoking habits,
otal cholesterol, number of metabolic syndrome components, presence of
eripheral vascular disease, electrical instability, residual ischemia, left
entricular ejection fraction, n-3 polyunsaturated fatty acids, vitamin E,
ntiplatelet agents, angiotensin-converting enzyme inhibitors, statins at six
onths, and beta-blockers.
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The Role of Metabolic Syndrome in Post-MI Patients July 19, 2005:277–83easons for this were not clear, but we hypothesize that it
ould be related to heavier risk factor burden and a longer
xposure to conventional and non-conventional risk factors
38).
In our study, patients with diabetes but not those with
ETS had an increased risk of hospitalization for CHF.
he United Kingdom Prospective Diabetes Study
UKPDS) showed that for every absolute 1% reduction in
bA1C there was a 16% reduction of risk of heart failure in
iabetic patients (39). We used, however, a hard definition
f heart failure (i.e., CHF that requires hospitalization), so
he small number of events may have impaired the statistical
ower; diabetic patients could have more severe forms of
HF requiring hospitalization.
tudy limitations. Our study shares the limitations of
ost-hoc analysis, and for the definition of obesity we
dopted an arbitrary cut point. No agreement exists on BMI
evel that can be considered equivalent to waist circumfer-
nce (40–44), and we finally selected a BMI 26 kg/m2,
ecause sensitivity analysis by using a BMI value of 28 and
9 kg/m2 (corresponding to the upper quartile and upper
uintile) did not show differences in prognostic capacity of
ETS. Moreover, the area under the receiver-operating
urves, using the three different cut points of 26, 28, and 29,
id not yield significantly different results.
In conclusion, METS and diabetes—two conditions
elated to IR—were found in one-half of the patients
urviving MI and were associated with progressively wors-
ning prognosis, despite the preventive measures already
dopted, suggesting that there is room for a more aggressive
herapeutic strategy having lifestyle modifications as corner-
tone.
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